Genotyping and drug-resistance testing in infectious diseases e.g. HIV, TB, SARS-CoV-2.
Try our Exatype Analysis Solution for Free
Sign up at ngs.exatype.com and run your first samples for free!
Pairing Hyrax Biosciences' Exatype platform with Roche's KAPA HyperCap and KAPA HyperPETE workflows provides integrated, end-to-end solutions from sample prep through to data analysis, interpretation and reporting.
Exatype supports the automated analysis of data generated from Roche’s KAPA HyperCap SARS-CoV-2 Panel (RUO) thereby making sequencing for SARS-CoV-2 genomic surveillance faster, cheaper and more accurate.
Report variant prevalences with confidence
Harness the power of Exatype’s algorithms in detecting low abundance variants e.g. surveillance studies and detection of dual-infection
Intuitive drag-and-drop interface means minimal end-user input needed to analyse data
Scale up with ease using Hyrax Biosciences’ streamlined and secure, cloud-based IT infrastructure
Confidently detect and report variants with the Exatype platform
Report your findings faster by on-cloud parallel processing using the intuitive interface of the Exatype platform
Hyrax Biosciences’ proven expertise in viral-sequence analysis and reporting offers reliable variant detection and surveillance
APIs enable direct integration with sequencers and/or LIMS (contact us for more information)
Our modular platform can analyse and interpret sequence data from an ever-expanding range of applications, including:
Genotyping and drug-resistance testing in infectious diseases e.g. HIV, TB, SARS-CoV-2.
Multi-target diagnostics, e.g. infectious disease panels.
Tumour profiling and drug-susceptibility testing in cancer.
Low abundance variant detection e.g. detecting mixed infections or the detection of biomarkers in liquid biopsies.